Complex assessment of a plasmid DNA mechanism of action in development of gene-activated materials

The number of studies related with gene-activated matrices is increasing annually; the first-in-class product has been already implemented into clinical practice for bone grafting indications. Considering specificity of the gene-activated matrices mechanism of action determined by gene constructs, there is a demand to standardize the methods allowing to characterize all the stages of biological action in vivo. Here, using on the example of a gene-activated hydrogel consisting of type I collagen and plasmid DNA with the vascular endothelial growth factor gene (VEGF165), the main steps of the plasmid DNA mechanism of action were confirmed by various methods. For this, a fluorescent Cy3, reporter plasmid DNA with the firefly luciferase gene (Luc), RT-PCR and ELISA, immunohistochemical study with antibodies to CD31 were used. The results were compared with the other scientific papers, some recommendations were formulated to determine a minimally required list of studies for the development of gene-activated materials.

[1]  P. Procter,et al.  The Few Who Made It: Commercially and Clinically Successful Innovative Bone Grafts , 2020, Frontiers in Bioengineering and Biotechnology.

[2]  D. Mantovani,et al.  Non-Viral in Vitro Gene Delivery: It is Now Time to Set the Bar! , 2020, Pharmaceutics.

[3]  H. Sadeghpour,et al.  Double domain polyethylenimine-based nanoparticles for integrin receptor mediated delivery of plasmid DNA , 2018, Scientific Reports.

[4]  S. Hill,et al.  Molecular Pharmacology of VEGF-A Isoforms: Binding and Signalling at VEGFR2 , 2018, International journal of molecular sciences.

[5]  A. Rizvanov,et al.  Use of Gene-Activated Demineralized Bone Allograft in the Therapy of Ulnar Pseudarthrosis. Case Report , 2017 .

[6]  R. Deev,et al.  World's First Clinical Case of Gene-Activated Bone Substitute Application , 2016, Case reports in dentistry.

[7]  S. Geary,et al.  Bone Regeneration Using Gene-Activated Matrices , 2016, The AAPS Journal.

[8]  G. Calin,et al.  Progresses towards safe and efficient gene therapy vectors , 2015, Oncotarget.

[9]  Gang Wu,et al.  Porous Chitosan Scaffolds with Embedded Hyaluronic Acid/Chitosan/Plasmid-DNA Nanoparticles Encoding TGF-β1 Induce DNA Controlled Release, Transfected Chondrocytes, and Promoted Cell Proliferation , 2013, PloS one.

[10]  M. Isaguliants,et al.  Evaluation of immunogen delivery by DNA immunization using non-invasive bioluminescence imaging , 2013, Human vaccines & immunotherapeutics.

[11]  Chun Wang,et al.  Transgene expression and local tissue distribution of naked and polymer-condensed plasmid DNA after intradermal administration in mice. , 2012, Journal of controlled release : official journal of the Controlled Release Society.

[12]  J. Jansen,et al.  The ability of a collagen/calcium phosphate scaffold to act as its own vector for gene delivery and to promote bone formation via transfection with VEGF(165). , 2010, Biomaterials.